Ocular Therapeutix™ Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BTIG Downgrades Ocular Therapeutix (OCUL) to Neutral
May 5, 2017 2:35 PM EDTBTIG downgraded Ocular Therapeutix (NASDAQ: OCUL) from Buy to Neutral. Analyst Dane Leone thinks there is risk of a delay in the current PDUFA date for Dextenza.
For an analyst ratings summary and ratings history on Ocular Therapeutix... More
Ocular Therapeutix (OCUL) Misses Q1 EPS by 10c
May 5, 2017 7:33 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.58), $0.10 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $475 thousand versus the consensus estimate of $470 thousand.
This is an important time for Ocular Therapeutix as we approach the PDUFA target action... More
